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Repeatability of [18F]FDG PET/CT total
metabolic active tumour volume and total
tumour burden in NSCLC patients
Guilherme D. Kolinger1, David Vállez García1, Gerbrand M. Kramer2, Virginie Frings2, Egbert F. Smit3,4,
Adrianus J. de Langen3,4, Rudi A. J. O. Dierckx1, Otto S. Hoekstra2 and Ronald Boellaard1,2*
Abstract
Background: Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly
studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we
investigated the repeatability of TMATV and TTB as function of uptake interval, positron emission tomography/
computed tomography (PET/CT) image reconstruction settings, and lesion delineation method. We used six lesion
delineation methods, four direct PET image-derived delineations and two based on a majority vote approach, i.e.
intersection between two or more delineations (MV2) and between three or more delineations (MV3). To evaluate
the accuracy of those methods, they were compared with a reference delineation obtained from the consensus of
the segmentations performed by three experienced observers. Ten NSCLC patients underwent two baseline whole-
body [18F]2-Fluoro-2-deoxy-2-D-glucose ([18F]FDG) PET/CT studies on separate days, within 3 days. Two scans were
obtained on each day at 60 and 90 min post-injection to assess the influence of tracer uptake interval. PET/CT
images were reconstructed following the European Association of Nuclear Medicine Research Ltd. (EARL) compliant
settings and with point-spread-function (PSF) modelling. Repeatability between the measurements of each day was
determined and the influence of uptake interval, reconstruction settings, and lesion delineation method was
assessed using the generalized estimating equations model.
Results: Based on the Jaccard index with the reference delineation, the MV2 lesion delineation method was the
most successful method for automated lesion segmentation. The best overall repeatability (lowest repeatability
coefficient, RC) was found for TTB from 90min of tracer uptake scans reconstructed with EARL compliant settings
and delineated with 41% of lesion’s maximum SUV method (RC = 11%). In most cases, TMATV and TTB repeatability
were not significantly affected by changes in tracer uptake time or reconstruction settings. However, some lesion
delineation methods had significantly different repeatability when applied to the same images.
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Conclusions: This study suggests that under some circumstances TMATV and TTB repeatability are significantly
affected by the lesion delineation method used. Performing the delineation with a majority vote approach
improves reliability and does not hamper repeatability, regardless of acquisition and reconstruction settings. It is
therefore concluded that by using a majority vote based tumour segmentation approach, TMATV and TTB in NSCLC
patients can be measured with high reliability and precision.
Keywords: Repeatability, Total tumour burden, Metabolic active tumour volume, FDG PET/CT, NSCLC, Tumour
delineation, Tracer uptake interval, Majority vote
Background
Quantitative evaluation of cancer therapy response is an
essential step towards effective and personalised patient
treatment. Positron emission tomography (PET)
combined with computed tomography (CT) using
[18F]2-Fluoro-2-deoxy-2-D-glucose ([18F]FDG) is a
powerful tool to provide predictive information on treat-
ment response in non-small cell lung cancer (NSCLC)
patients [1–4]. Despite the availability of a diversity of
metrics that can be derived from [18F]FDG PET/CT im-
ages, treatment response is usually measured using the
change in standardised uptake values (SUV) [5–8], even
though SUV is sensitive to a series of patient and scan
protocol factors and is only accurate when there is
homogeneous uptake in the tumour [9–12]. As a result,
interest in different quantitative features has been grow-
ing and, rather than evaluating individual lesions, there
is a shift towards metrics that better represent the pa-
tient’s total tumour load, such as the total metabolic ac-
tive tumour volume (TMATV) and total tumour burden
(TTB), also referred to as whole-body total lesion gly-
colysis (TLG) [13–17]. TMATV, for example, has been
found to be a significant prognostic factor for disease
progression, recurrence, and death [16, 18]. TTB com-
bines volumetric and metabolic information to represent
whole-body disease burden and is regarded as a strong
prognostic indicator for NSCLC, which can be import-
ant when defining treatment guidelines [13]. Despite this
increase in interest on whole-body metrics, the majority
of tumour test-retest studies only evaluated the repeat-
ability of SUV and primarily on lesion basis, which were
summarised by Lodge [19].
All quantitative measurements from [18F]FDG PET/
CT scans are affected by tracer uptake time and image
reconstruction settings [15, 20, 21]. To this end, the
European Association for Nuclear Medicine Research
Ltd. (EARL) has developed procedure guidelines for
[18F]FDG PET/CT tumour imaging to improve stand-
ardisation of uptake values in multicentre settings [22].
On the other hand, modern reconstructions include
resolution modelling based on the PET/CT system
point-spread-function (PSF) [23, 24] and are considered
state-of-the-art in clinical practice due to its higher reso-
lution and improved visual lesion detection. However,
use of PSF affects the metrics derived from PET images
[21, 25] and it is, at present, not compliant with the
current standardisation proposed by European Associ-
ation for Nuclear Medicine (EANM) guidelines. Conse-
quently, there is a high interest in exploring the
quantitative features extracted from PSF-reconstructed
PET images and to compare them with EARL compliant
metrics [25]. Of note, recently the feasibility of perform-
ance harmonisation using state-of-the-art PET/CT sys-
tems was shown, enabling the use of PSF reconstruction
in multicentre studies [26].
Moreover, there are many lesion delineation methods,
all of which are influenced by scan and reconstruction
parameters; hence, metrics that depend on the estimated
lesion volume such as TMATV and TTB are also af-
fected [14, 25, 27]. To address this performance variabil-
ity, it can be expected that a tumour delineation based
on the agreement of several delineation methods will
improve the reliability of the lesion segmentation against
image quality variations [28].
Therefore, the aim of this study is to assess the repeat-
ability of TMATV and TTB from whole-body [18F]FDG
PET/CT scans of NSCLC patients and to investigate its
sensitivity to image acquisition, reconstruction settings,
and lesion delineation method, including methods based
on the majority vote approach.
Methods
Patients
Ten NSCLC patients underwent a total of four baseline
whole-body [18F]FDG PET/CT scans on two different
days, within 3 days. At each day, scans were obtained at
both 60 and 90min post-injection. The scan at 90 min
post-injection of one patient on the second day was ex-
cluded due to excess movement. Another patient could
not undergo the scan at 90 min on the second day. Fur-
ther patient information and inclusion criteria can be
found in more detail in previous publications [15, 20]. A
subset from that data was used on the present study
since one patient from that dataset did not perform any
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scan on the second day and was excluded. Demograph-
ics of the patients are described in Table 1. All patients
gave written informed consent before enrolment, and
the study was approved by the Medical Ethics Review
Committee of the VU University Medical Center (Dutch
trial register [trialregister.nl] NTR3508).
[18F]FDG PET/CT acquisition and imaging processing
All PET/CT scans were obtained with a Gemini TF
PET/CT scanner (Philips Healthcare, Cleveland, OH,
USA). Patients fasted for 6 h or more. A low-dose CT
during normal breathing for attenuation correction was
performed, followed by a whole-body [18F]FDG PET
scan 60min after tracer injection. Thirty minutes later, a
second whole-body PET acquisition was performed.
After the second PET scan, a second low-dose CT was
done for attenuation correction. This procedure was re-
peated within 3 days of the first study. All PET data were
normalised and corrected for scatter and random events,
dead time, attenuation, and decay. Two reconstruction
protocols were applied to the PET images. The first re-
construction followed EARL compliant guidelines for
tumour imaging [22], while the second included reso-
lution modelling with PSF [23, 24] as implemented by
the scanner vendor.
Standard PET-based delineation methods
All images were segmented with four commonly used
and readily available (including in clinical software tools)
semi-automatic delineation methods [20, 22, 27, 29] with
an in-house developed software. The tumour’s contours
were defined by:
1. Fixed SUV threshold of 2.5 g/mL (SUV25)
2. Fixed SUV threshold of 4.0 g/mL (SUV40)
3. Adaptive at 41% of each lesion’s maximum SUV
(41MAX)
4. Contrast corrected for local tumour to background
activity at 50% of the peak SUV (A50P)
Note that SUV25 and SUV40 are simple methods
based on fixed SUV threshold, 41MAX is adaptive to
each lesion’s condition, drawing a mask at 41% of its
SUVmax without regard to background activity, and
A50P adaptively corrects for source to local background
activity ratio and the method is able to segment lesions
also in case tumour uptake would be lower than twice
the local background. Local background activity was de-
fined as a single-voxel 3D shell around each masked re-
gion, 2.5 cm away from the edges of an isocontour
defined at 70% of the SUVmax value, excluding voxels
with a value higher than 2.5. The mean uptake of this
shell was considered the reference value for the local
background activity [27]. The peak SUV was defined as
a 1 mL sphere volume of interest with the highest SUV
average across all positions within a lesion [29].
Consensus contours
In addition to these four PET image-based delineation
methods, two consensus contours were drawn using a ma-
jority vote (MV) approach. These consensus methods
were based on the intersection of the four above-men-
tioned PET-based delineations, i.e. if a number of methods
agree that a voxel is part of the lesion, then it will also be
included in the consensus delineation:
1. MV2: Agreement between 2, 3, or 4 of the standard
PET-based methods
Table 1 Patient demographics and scan characteristics
Characteristic Overall Scans at day 1 Scans at day 2
Patients 10
Gender ratio (M/F) 1.5






Squamous cell carcinoma 3
Weight (kg) 76 [57–110] 75 [57–113]
Injected activity (MBq) 248 [194–377] 238 [192–392]
Scan start time (min)
Uptake time goal of 60 min 61 [59–67] 60 [60–63]
Uptake time goal of 90 min 92 [90–97] 90 [90–95]
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2. MV3: Agreement between 3 or 4 of the standard
PET-based methods
Expert observer delineations
Images from the first day, acquired 60min post-injection
and reconstructed following EARL settings were
assessed by three experienced observers (AB, RB, WN).
The observers were blind to these conditions and did
not know what images were being assessed. These im-
ages were chosen for their compliance with EANM
Guidelines for NSCLC studies [22]. The observers per-
formed segmentations assisted by the same in-house de-
veloped software used for the semi-automatic
delineations. A whole-body automatic delineation of all
[18F]FDG avid regions of the PET images was drawn
using the SUV40 method, then the observers had to re-
move any region they considered to be physiological up-
take and not a lesion. Next, the observers could add any
region perceived as lesion that was missed by the auto-
matic method. The SUV threshold for the delineations
was adjusted with a slider, fine-tuning the segmentation
of all regions at once. This procedure was repeated after
12 (AB), 7 (RB), and 13 (WN) days with images from the
second day of scans (again 60 min post-injection scan;
EARL compliant reconstruction). It was then possible to
address the repeatability of the observers. Most import-
antly, the intersection of these delineations was evalu-
ated at each day and, with a consensus approach, a
reference delineation (RD) was created for each day:
RD1 and RD2, respectively.
Metrics
PET images were analysed with the six semi-automatic de-
lineation methods. Therefore, each patient had 4 scans × 2
reconstructions × 6 semi-automatic segmentations = 48
possibilities studied. Additionally, the experienced ob-
servers and reference delineations were studied. For each
possibility, the total segmented volume, summed over all
lesions, was measured as TMATV. Furthermore, TLG was
calculated per lesion as the MATV multiplied by its average
SUV (SUVmean). The TTB of a patient is thus defined as
the whole-body TLG, i.e. the sum of TLG over all lesions.
Delineation success of semi-automatic methods
The six semi-automatic delineation methods were com-
pared against the reference delineation obtained from
the expert observers. The Jaccard index (JI) between the
TMATV from the RD and each semi-automatic method
was calculated for each scan day, only for images ac-
quired 60min post-injection and reconstructed with
EARL compliant settings. A JI of 1.0 represents a perfect
coincidence of volumes, while an index of 0.0 means
there is no intersection between the two volumes. The JI
between volumes A and B is defined as follows:
JI A;Bð Þ ¼ A∩B
A∪B
Repeatability analysis
The repeatability (or test-retest) of TMATV and TTB
were determined by the difference and relative difference
between the values measured at each day. This was done
for each combination of tracer uptake interval, recon-
struction settings, and delineation method. The
test-retest (TRT) was calculated as follows:
TRT ¼ day2−day1
TRT% ¼ 100 day2−day1
day1þ day2ð Þ=2
where day1 and day2 are the metrics (TMATV or TTB)
determined at the same time point on both days. Follow-
ing, the absolute of TRT and TRT% were also computed
and indicated as aTRT and aTRT%. Additionally, intraclass
correlation coefficients (ICC) were calculated to assess the
agreement between the measurements at each day (two-
way mixed model; consistency type; single measures).
The repeatability coefficient (RC) was calculated as the
standard deviation (SD) of the respective TRT and
TRT% of each combination of uptake interval, recon-
struction settings, and lesion delineation (10 patients per
combination) multiplied by 1.96:
RC ¼ 1:96 SD
According to previous literature, the mean difference
± RC provides an interval within which 95% of the dif-
ferences between measurements of two consecutive
measurements are expected to lie [19, 30].
Statistical analysis
In order to study the effects of reconstruction settings,
tracer uptake time, and delineation method on the re-
peatability of TMATV and TTB, the present data was
analysed using the generalized estimating equations
(GEE) statistical model [31–33]. The GEE model is
known to achieve higher statistical power with small
sample sizes, repeated measurements, and with miss-
ing data than the repeated measures ANOVA [32],
and its known to be less affected by violations on the
distribution assumption, as it only requires the cor-
rect specification of marginal mean and variance as
well as the link function [33]. The best working cor-
relation matrix, based on the quasi-likelihood under
the independence model information criterion values
was the exchangeable matrix, and an identity link
function was used. The Wald test was used to report
the p values, and p < 0.05 was considered significant,
without correction for multiple comparisons.
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To assess the differences between the repeatability of
the semi-automatic delineation methods and how they
were affected by tracer uptake time and image recon-
struction settings, their repeatability (as TRT%) were in-
cluded in the GEE model as dependent variables, and
the patient number, tracer uptake interval, reconstruc-
tion settings, and delineation method were included as
predictors (i.e. independent variables) for the model, as
well as their interactions (with the exception of the in-
teractions with the patient number, as this variable was
included in the model to account for the missing data).
The ICC and the GEE statistical analyses were carried
out using the SPSS software package (version 23.0, IBM,
Armonk, NY, USA). Results are presented as mean dif-
ference ± standard error, unless mentioned differently.
Results
TMATV and TTB values distribution
Scan protocol, reconstruction settings, and delineation
method affected the metrics acquired from the [18F]FDG
PET/CT scans. Therefore, the median and range of the
data acquired for the patients will vary case by case. The
data from the expert delineations and the reference can
be seen in Fig. 1 for TMATV and TTB. Note the vari-
ability between observers, especially the median value
(black horizontal line inside the box). Furthermore, RD
compensates some of the inter-observer variability and
its median values are between the values from individual
observers. The TMATV acquired from the semi-auto-
matic delineation methods can be seen in Fig. 2 (to-
gether with RD for comparison). The plot is displayed in
a log-scale for better visualisation, since there is a large
spread of the data (e.g. mainly small volumes in most of
the tumours, with few cases with extremely large vol-
umes). It was possible to observe that fixed SUV thresh-
old methods (SUV25 and SUV40) segmented, in general,
larger volumes than 41MAX and A50P. As a natural
consequence, MV2 presents larger volumes than MV3.
Additionally, Fig. 2 illustrates the effect of a longer tracer
uptake interval on TMATV, resulting in larger volumes.
This effect is more pronounced on the standard
PET-based delineation methods than on consensus
methods.
Delineation accuracy
The Jaccard index of each of the six semi-automatic de-
lineation methods (when compared with RD1 and RD2)
can be seen on Fig. 3 (images acquired at 60 min
post-injection, and reconstructed with EARL compliant
settings). Each patient is displayed with a different
symbol, illustrating the varying JI scores of each delinea-
tion method and that no method was consistently the
worst or the best for different patients. This is a conse-
quence of the fact that a certain semi-automatic delinea-
tion method might be accurate for one patient while
failing to delineate another patient, even under the same
image settings. Figure 3 also demonstrates that MV2’s JI
were, in general, higher than the scores from other
methods. Table 2 shows the average JI and its interquar-
tile range of the semi-automatic delineation methods
(with RD1 and RD2).
The consensus contour MV2 has the highest average
score for both days (0.71 and 0.70) and the smallest
interquartile range (0.18 and 0.32). Following, the sec-
ond highest average JI was obtained with 41MAX (0.64
and 0.65) and the method with the lowest average score
Fig. 1 Box plots with median and range of TMATV (left panel) and TTB (right panel). Both panels show data from the delineations in images
acquired at the first and second day of scans, indicated by the colours. Images were acquired 60 min post-injection and reconstructed following
EARL compliant settings. TMATV in milliliter and TTB in grams
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Fig. 2 Box plots with median and range of TMATV (mL). Y-axis in log-10 scale for better visualisation; outliers included. Panels on the left show
the values acquired from EARL compliant reconstruction by the six semi-automatic delineation methods as well as the reference delineation
(horizontal axis). On the right panels, data from images with PSF reconstruction. On the top row, data from the test (day 1 of scans) is displayed,
while on the bottom row from retest (day 2 of scans). Data from scans acquired 60 or 90 min post-injection are colour-coded
Fig. 3 Jaccard index for all patients delineated with the semi-automatic delineation methods (when compared against RD) for day 1 (left panel)
and day 2 (right panel). Each patient is displayed with a different symbol
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was A50P (0.5). Some examples of the delineations on
images acquired 60 min post-injection and reconstructed
with EARL compliant settings can be seen in Additional
file 1: Figure S1.
Additional file 1: Table S1 presents the average JI and its
interquartile range of the semi-automatic delineation
methods applied to both EARL and PSF reconstruction set-
tings, as well as for images acquired 90min post-injection.
Repeatability: experienced observers
The repeatability of each experienced observer and of the
RD can be seen in Table 3, where the average (from the 10
patients) TRT, TRT%, their respective RC, and ICC values
are displayed for TMATV and TTB. Figure 4 shows the
box plots for TRT% of each experienced observer and of
RD. Observer’s repeatability was low, with up to 50%
TMATV variation. Furthermore, this assessment was
highly dependent on the observer and a consensus between
the expert observers lowered TRT% variability (Table 3).
Repeatability: semi-automatic delineation methods
A summary of repeatability, RC, and ICC for all
semi-automatic delineation methods applied to both up-
take intervals and reconstructions can be found in Ta-
bles 4 and 5 for TMATV and TTB, respectively (RD is
shown together for comparison). The best overall repeat-
ability, as defined by the lowest RC%, was found for
TTB derived from 90min post-injection scans with
EARL compliant reconstruction and 41MAX delineation
method (RC = 11%). Furthermore, the same method
under the same parameters had the best TMATV re-
peatability (RC = 14.3%). The summary for aTRT and
aTRT% for both TMATV and TTB are shown in
Additional file 1: Table S2 and Table S3, in which the
lowest RC values are 8.9% for TMATV (60 min of up-
take, PSF reconstruction, A50P delineation) and 5.5% for
TTB (90 min of uptake, EARL compliant reconstruction,
41MAX delineation).
All TMATV ICCs are higher than 0.90, except for
A50P and MV3 applied to EARL compliant images at
90 min post-injection (both with ICC = 0.83), and
SUV25 applied to PSF images at 90 min post-injection
(ICC = 0.65). TTB had overall higher ICC than TMATV,
with values equal to or higher than 0.90 for all delinea-
tion methods, regardless of uptake interval and image
reconstruction settings.
Repeatability: impact of tracer uptake interval
The overall effect of tracer uptake time on TMATV
(− 1.34% ± 4.49%; p = 0.766) and TTB (2.14% ± 5.57%;
p = 0.701) repeatability was not significant. TMATV
repeatability of specific delineation methods and re-
construction settings was not affected by changes in
tracer uptake interval. Similarly, TTB repeatability
was not affected by using a specific reconstruction
and delineation method.
Repeatability: impact of reconstruction settings
Changes in reconstruction settings were not a significant
factor impacting TMATV (− 0.43% ± 1.96%; p = 0.827)
Table 2 Jaccard index and interquartile range
Delineation method Day 1 Day 2
Average JI Interquartile range Average JI Interquartile range
SUV25 0.62 [0.48–0.73] 0.55 [0.39–0.72]
SUV40 0.62 [0.54–0.77] 0.59 [0.46–0.80]
41MAX 0.65 [0.45–0.88] 0.64 [0.45–0.85]
A50P 0.50 [0.37–0.65] 0.50 [0.35–0.67]
MV2 0.71 [0.61–0.80] 0.70 [0.54–0.86]
MV3 0.58 [0.39–0.77] 0.56 [0.40–0.79]
Average Jaccard index and the interquartile range of each semi-automatic delineation method. JI with the reference delineation of each day, RD1 and RD2,
respectively. For scans acquired 60 min after injection and reconstructed following EARL compliant settings
Table 3 Repeatability of experienced observers and reference delineation
Observer TMATV TTB
TRT (RC) TRT% (RC%) ICC TRT (RC) TRT% (RC%) ICC
AB 4.2 (98) 1.6 (53) 0.95 83 (426) 3.2 (37) 0.99
RB 4.6 (73) 2.5 (76) 0.97 94 (631) − 0.5 (54) 0.98
WN − 43.7 (161) − 28.6 (86) 0.79 − 121 (648) − 19.1 (66) 0.98
RD − 5.7 (82) − 9.8 (61) 0.96 41 (505) − 4.6 (43) 0.99
Average repeatability and repeatability coefficient and corresponding ICC of total metabolic active tumour volume (TMATV) and total tumour burden (TTB) for the
three experienced observers and the reference delineation. TRT in mL and TRT% in percentage
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and TTB (1.78% ± 2.22%; p = 0.422) repeatability. Repeat-
ability of metrics from scans at different uptake intervals
was not significantly affected by different reconstruc-
tions. However, the SUV25 delineation method had sig-
nificantly different TMATV repeatability with different
reconstructions (− 9.87% ± 4.19%; p = 0.018), while other
methods did not (p ≥ 0.300). Nevertheless, at specific up-
take interval using a certain delineation method, changes
in reconstruction settings did not affect TMATV repeat-
ability. TTB repeatability was more robust and was not
affected by changes in reconstruction settings, regardless
of tracer uptake time or delineation method.
Repeatability: impact of lesion delineation method
The delineation method had overall significant impact
on the repeatability of both TMATV (p < 0.001) and
TTB (p = 0.007). At 60 min post-injection, repeatability
was significantly different whether delineations were
performed with 41MAX or MV3 methods (TMATV
TRT% 5.21% ± 2.58%, p = 0.044; TTB TRT% 3.78% ±
1.84%, p = 0.040), while for scans with 90 min of tracer
uptake, A50P and MV2 provided significantly different
TMATV repeatability (4.85% ± 2.39%; p = 0.042), re-
gardless of reconstruction settings. EARL compliant re-
constructions did not provide significantly different
repeatability by the use of different delineation
methods; however, with PSF reconstruction, it had im-
pact on the repeatability of 41MAX as compared with
MV3 (TMATV TRT% 3.06% ± 1.39%, p = 0.028; TTB
TRT% 1.89% ± 0.90%, p = 0.036), regardless of tracer
uptake time. Additionally, at a complete specification of
tracer uptake interval and reconstruction settings, only
41MAX compared with MV3 had significantly different
TMATV repeatability (6.65% ± 3.38%; p = 0.049; scan
60 min post-injection, EARL compliant reconstruction).
Discussion
In the present work, we studied the repeatability of two
whole-body metrics (TMATV and TTB) and how they
vary as a function of tracer uptake interval, PET/CT image
reconstruction settings, and tumour delineation method.
We found that the delineation performed by the consen-
sus method MV2 was more reliable than any other stand-
ard PET-based semi-automatic segmentation method
included in this study (JI = 0.7). However, the best repeat-
ability was obtained with 41MAX (RC = 11% for TTB
from EARL compliant image and scan 90min after injec-
tion). MV2 had its best repeatability for TMATV under
the aforementioned settings with RC = 15%.
One important aspect to address regarding semi-auto-
matic delineation methods is their concordance with a
segmentation that would be performed by an expert
Fig. 4 Box plots of TMATV (left panel) and TTB (right panel) repeatability from the three experienced observers and their consensus, RD
Table 4 Total metabolic active tumour volume repeatability for
different tracer uptake intervals, reconstruction settings, and
lesion delineation methods
Method 60min of uptake 90 min of uptake
TRT (RC) TRT% (RC%) ICC TRT (RC) TRT% (RC%) ICC
EARL
SUV25 29.7 (211) 5.9 (51) 0.93 9.4 (35) 3.7 (15) 1.00
SUV40 2.5 (44) 1.0 (31) 0.99 3.5 (17) 7.9 (32) 1.00
41MAX 4.5 (35) 7.8 (45) 0.99 6.5 (30) 3.0 (14) 1.00
A50P 0.4 (38) 5.9 (49) 0.92 16.2 (77) 10.5 (37) 0.83
MV2 9.4 (48) 9.3 (44) 0.99 5.4 (24) 3.5 (15) 1.00
MV3 − 4.2 (36) 1.2 (39) 0.94 15.7 (78) 9.1 (38) 0.83
RD − 5.7 (82) − 9.8 (61) 0.96
PSF
SUV25 46.0 (171) 14.9 (44) 0.95 139.5 (738) 14.4 (63) 0.65
SUV40 3.4 (23) 1.8 (29) 1.00 3.8 (19) 5.6 (22) 1.00
41MAX 3.2 (17) 6.9 (35) 1.00 17.4 (92) 6.2 (30) 0.92
A50P 2.1 (15) 0.2 (19) 0.99 5.7 (19) 8.2 (21) 0.98
MV2 5.4 (25) 3.0 (35) 1.00 14.5 (75) 5.6 (22) 0.98
MV3 2.8 (14) 3.1 (18) 1.00 3.7 (20) 3.9 (21) 0.98
Average and repeatability coefficient of total metabolic active tumour volume
(TMATV) repeatability for different tracer uptake intervals, reconstruction
settings, and lesion delineation methods, including the corresponding ICC. TRT
in mL and TRT% in percentage
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observer. In this study, the reference delineation was a
consensus between three expert observers. Figure 2
shows that the data from RD falls in between the values
acquired by the four standard PET-based semi-automatic
methods. From that, it can be expected that a consensus
method would coincide with RD, which is what is seen
in Table 2, where MV2 has the highest JI for both days
(JI = 0.7). Furthermore, MV2 had the smallest interquar-
tile range of all methods, showing its reliability to pro-
vide a good segmentation regardless of the patient’s
condition. It might be considered that a JI = 0.7 is not
sufficiently high to be defined as a reliable method; how-
ever, it is important to notice that the approach for cre-
ating the reference delineation used on the current study
is far from the daily clinical routine (i.e. three observers
assessing each image), in addition to the high
inter-observer variability they presented. Furthermore,
previous studies [34, 35] suggested that different lesion
delineation methods had similar prognostic value for
progression-free survival and overall survival accuracy,
at least in the context of lymphoma patients, despite the
large difference in MATV resulting from these different
methods. These studies highlight that despite possible
technical and conceptual flaws of basic PET-based lesion
delineation methods, they are still successful prognostic
factors. Therefore, not necessarily the actual accuracy of
segmentation but good reliability and reproducibility
might be of more importance in a diagnostic or prognostic
setting (not in a radiotherapy setting).
Table 3 shows that the repeatability of the expert de-
lineations is improved by taking their consensus.
However, even this RD’s TMATV repeatability showed
lower performance than the ones obtained in any of the
semi-automatic methods (Table 4). Although RD’s TTB
repeatability was better than the semi-automatic delinea-
tion methods (for 60 min of tracer uptake scans recon-
structed with EARL compliant settings), Table 3 shows
that the individual observer repeatability is highly variable,
highlighting the strong dependence on the observer for a
reliable assessment, while semi-automatic delineation
methods are observer independent. Nevertheless, the
TMATV repeatability obtained with the semi-automatic
delineation methods was not significantly different than
those obtained by the semi-automatic delineation
methods (Additional file 1: Table S4).
The segmentations’ reliability obtained in this study is
in line with previous work performed by Schaefer et al.
[28], where the performance of the consensus method
was investigated at a lesion level. That study found that
consensus approaches never provided the worst delinea-
tion when compared to its reference. In the present
study, MV2 and MV3 never had the lowest JI (Fig. 3)
and MV2 had the lowest JI interquartile range for both
scan days (Table 2).
Kramer et al. [15] had previously reported a repeatabil-
ity coefficient (from TRT%) of 31% for metabolic active
tumour volume (MATV) and 24% for TLG (scan 90 min
post-injection, EARL compliant reconstruction, and
A50P delineation method), metrics analogous to the
ones in the current study. Such results are either worse
(MATV) or on par (TLG) with most RC% obtained in
the current study from the semi-automatic delineation
Table 5 Total tumour burden repeatability for different tracer uptake intervals, reconstruction settings, and lesion delineation methods
Method 60 min of uptake 90 min of uptake
TRT (RC) TRT% (RC%) ICC TRT (RC) TRT% (RC%) ICC
EARL
SUV25 322 (1560) 5.8 (56) 0.95 59 (319) 4.0 (18) 1.00
SUV40 236 (1149) 3.7 (54) 0.97 38 (252) 8.4 (34) 1.00
41MAX 122 (611) 8.9 (47) 0.93 59 (169) 3.1 (11) 1.00
A50P 126 (667) 7.6 (56) 0.90 92 (287) 9.7 (36) 0.99
MV2 257 (1133) 9.4 (54) 0.97 44 (257) 4.1 (21) 1.00
MV3 96 (633) 3.7 (48) 0.93 91 (282) 8.4 (35) 0.99
RD 41 (505) − 4.6 (43) 0.99
PSF
SUV25 309 (1069) 9.1 (45) 0.98 462 (2490) 10.0 (41) 0.93
SUV40 133 (780) 1.2 (39) 0.99 41 (260) 6.3 (26) 1.00
41MAX 65 (326) 3.1 (38) 0.98 83 (272) 5.9 (22) 0.99
A50P 60 (355) − 1.2 (32) 0.97 64 (182) 8.6 (28) 1.00
MV2 138 (778) 1.4 (42) 0.99 70 (333) 5.7 (24) 1.00
MV3 62 (322) 0.8 (28) 0.98 44 (115) 4.5 (17) 1.00
Average and repeatability coefficient of total tumour burden (TTB) repeatability for different tracer uptake intervals, reconstruction settings, and lesion delineation
methods including the corresponding ICC. TRT in mL and TRT% in percentage
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methods. Kramer et al. additionally assessed repeatability
when using the PERCIST averaged criteria to select le-
sions (the PERCIST criteria selects only up to the five
hottest lesions [36], and their uptake was averaged into a
single value) and achieved repeatability coefficients of
13% for MATV and 10% for TLG, reaching values com-
parable to the best ones found in the current study,
where we specifically studied whole body metrics. Com-
paring our results with those seen by Kramer et al., we
therefore suggest that good repeatabilities can be ob-
tained for NSCLC whole body metrics, as long as either
41MAX or MV2 are used for lesion delineation.
Other lung cancer studies reported repeatability based
on the absolute difference between the repeated mea-
surements [29, 37]. Nakamoto et al. [37] reported the
standard deviation of the measured repeatability, and by
multiplying it by 1.96, it is possible to estimate RC from
that study. Therefore, a tumour volume repeatability
with (estimated) RC = 5.0% was found. Furthermore,
Nakamoto et al. also studied a metric similar to TTB,
namely effective glycolic volume (product between the
voxel volume and its SUV, then summed for all of the le-
sion’s voxels), and found (estimated) RC = 16% (scan 50–
60min post-injection, and tumour delineation based on
a background adaptive method). From 60min
post-injection scans, the current study has lowest
TMATV RC = 8.9% (PSF reconstruction; A50P delinea-
tion method) and TTB RC = 15% (PSF reconstruction;
MV3 delineation method) from aTRT%. Nakamoto et al.
found lower (estimated) RC for both tumour volume
and burden, which might be a consequence of only
selecting lesions larger than 2.0 cm in all three dimen-
sions (as determined by CT), avoiding partial volume ef-
fects. Their method, therefore, does not include the total
tumour load in the body, unlike ours.
Frings et al. [29] reported TMATV RC = 44% and for
lesions larger than 4.2 mL, RC = 21.9% (scans 45–60 min
post [18F]FDG injection; delineation at 41% of SUVmax
adapted for background), inferred from aTRT%. In the
current study, both lower and higher RC values from
aTRT% were found, depending on the delineation
method. The best TMATV repeatability found (from
aTRT%) was RC = 8.9% (60 min post-injection scan, PSF
reconstruction, A50P delineation method).
Consistent with the results seen by Kramer et al.
[15], we also observed that, in general terms, TMATV
and TTB repeatabilities were not affected by tracer
uptake time and reconstruction settings, but for a few
specific cases with certain delineation methods. As
seen previously [14, 20, 38], both TMATV and TTB
repeatabilities were, overall, significantly dependent
on the applied delineation method.
The main limitation of this study is the small sample
size, consisting of ten patients scanned in a single PET/
CT system. Furthermore, only a single lesion type
(NSCLC, including extra-thoracic lesions) was consid-
ered and it was not feasible to perform fully manual seg-
mentation of lesions as reference. However, the strength
of the data is that we could compare segmentation per-
formance of several semi-automatic methods against a
reference derived from three expert observers and in a
head to head comparison across variously applied tracer
uptake intervals and reconstruction settings.
In conclusion, this study suggests that for [18F]FDG
PET/CT studies in advanced stage NSCLC patients, a con-
sensus approach (MV2) provides the best trade-off be-
tween most reliable delineation and overall repeatability
performance. Furthermore, the PET-based semi-automatic
delineation methods used as input for MV2 are simple
and readily available. Therefore, its implementation seems
feasible in most centres. However, if this consensus ap-
proach cannot be made widely available or shared in mul-
ticentre setting, the 41MAX method is the best
alternative, since it also provides reliable segmentations
and has the lowest RC% across all methods tested. Yet,
one should be aware that the actual TMATV and TTB
values obtained depend on the segmentation (Fig. 2) and
the used delineation method should thus be consistently
applied by all sites.
Conclusion
In this study, we assessed the repeatability of total meta-
bolic active tumour volume and total tumour burden in
stage 3 and 4 NSCLC patients as a function of tracer up-
take interval, image reconstruction settings, and lesion
delineation method. We showed that, in most cases,
changes in these parameters do not significantly affect
TMATV and TTB repeatability. The consensus ap-
proach, MV2, was the most robust for accurately seg-
menting lesions. Based on delineation reliability and
overall TMATV and TTB repeatability performance, a
consensus segmentation approach, based on the majority
vote method, is the most preferred semi-automated
method for total tumour burden assessments in NSCLC
[18F]FDG PET/CT studies.
Additional file
Additional file 1: Table S1. Jaccard index and interquartile range of the
semi-automatic delineation methods. Table S2. Total Metabolic Active
Tumour Volume absolute repeatability for different tracer uptake intervals,
reconstruction settings, and lesion delineation methods. Table S3. Total
Tumour Burden absolute repeatability for different tracer uptake intervals,
reconstruction settings, and lesion delineation methods. Table S4.
Comparison of the TMATV repeatability obtained by RD and the
semi-automatic delineation methods. Figure S1. Example of delineations
performed by the consensus between three experienced observers
(Reference delineation), and six semi-automatic methods with contour at:
fixed SUV threshold of 2.5 g/mL (SUV25), fixed SUV threshold of 4.0 g/mL
(SUV40), at 41% of lesion’s maximum SUV (41MAX), contrast corrected for
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local tumour to background activity at 50% of peak SUV (A50P),
agreement between two or more of the previous methods (MV2), and
agreement between three or four of the previous methods (MV3). Image
acquired 60min post-injection and reconstructed following EARL compliant
settings. (DOCX 4220 kb)
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